Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Share Purchase Price: 1607.6318 pence per share.
- Transaction Date: January 10, 2014.
Material Changes
The filing reports an increase in the holding of Ordinary Shares by a connected person, Dr. S. Dexter, following the re-investment of a dividend paid on January 9, 2014, and a subsequent purchase of shares. No material changes to the company's overall financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a specific insider transaction under Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Dr. S. Dexter (Connected Person) acquired 148 Ordinary Shares.
- The transaction involved dividend re-investment and a direct purchase at 1607.6318 pence per share.
- The transaction was notified to the company on January 15, 2014, and filed on January 16, 2014.
- This document does not contain quarterly or annual financial performance data.